V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10442216 | 10041887 | 1.49 | 61.6 | null | 2017-01-09 | 2017-01-09 | Cyclophosphamide Weekly PO | 02 | null | CYCLOPHOSPHAMIDE + OBINUTUZUMAB + VINCRISTINE | 100881381 |
| 10442274 | 10041888 | null | null | Curative (C) | 2017-08-24 | 2017-09-07 | Atezolizumab | 02 | N | MELPHALAN | 100643558 |
| 10442315 | 10041889 | 1.81 | 92 | null | 2022-02-05 | 2022-02-07 | null | 02 | null | CAPECITABINE + MITOMYCIN + RT | 101315074 |
| 10442460 | 10041890 | 1.62 | 88.2 | Curative (C) | 2021-01-01 | 2021-02-04 | Bexarotene | 02 | null | AC | 100057798 |
| 10442682 | 10041893 | null | 0 | 03 | 2018-09-17 | 2018-09-25 | Vinorelbine (oral) | 01 | N | CARBOPLATIN + EPIRUBICIN + PACLITAXEL | 101417153 |
| 10442683 | 10041894 | 1.74 | 77.5 | null | 2019-06-12 | 2019-06-20 | CAPECITABINE + CARBOPLATIN + EPIRUBICIN | 02 | null | PEG INTERFERON | 101579478 |
| 10442801 | 10041895 | 1.64 | 72.9 | null | 2018-01-08 | 2018-01-09 | RIALTO TRIAL | 02 | null | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 101071804 |
| 10442870 | 10041896 | 1.6 | 0 | Curative (C) | 2017-05-13 | 2017-05-20 | Oxaliplatin + Modified de Gramont | 02 | N | CAPECITABINE + RT | 100932057 |
| 10442989 | 10041897 | 1.94 | 90 | Palliative (P) | 2016-10-27 | 2016-11-10 | Trastuzumab | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100390961 |
| 10443047 | 10041898 | 1.56 | null | Adjuvant (A) | 2017-12-19 | 2018-01-03 | Melphalan IV High dose | 02 | N | MELPHALAN | 100631247 |
| 10443050 | 10041899 | 1.53 | 112 | Curative (C) | 2018-08-23 | 2018-08-23 | null | null | null | GEMCARBO | 100517493 |
| 10443134 | 10041901 | 1.58 | 100.5 | null | 2017-01-17 | 2017-01-24 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB + VINCRISTINE | 02 | null | OSIMERTINIB | 101088808 |
| 10443207 | 10041903 | 1.7 | 67.8 | Curative (C) | 2016-02-26 | 2016-02-28 | DA 3+8 | 02 | N | CETUXIMAB | 100925145 |
| 10443238 | 10041904 | 1.71 | 80.4 | Palliative (P) | 2016-08-29 | 2016-08-29 | METHOTREXATE | 02 | N | SCALOP-2 TRIAL | 100560162 |
| 10443345 | 10041906 | 1.6 | 74.6 | Adjuvant (A) | 2018-09-05 | 2018-09-05 | Capecitabine (21days) + Carboplatin | 02 | N | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN | 101810969 |
| 10443425 | 10041907 | null | null | Curative (C) | 2022-01-13 | 2022-02-11 | Arsenic Triox + Tretinoin Ind W1-4 | null | null | CISPLATIN + DOCETAXEL + FLUOROURACIL | 100029989 |
| 10443494 | 10041909 | 1.58 | 70.2 | 03 | 2019-06-06 | 2019-06-06 | Bortezomib + Daratumumab | 02 | null | IRINOTECAN + MDG | 101130121 |
| 10443511 | 10041910 | 1.75 | 101.2 | Curative (C) | 2019-01-08 | 2019-01-20 | FEC + DOCETAXEL + TRASTUZUMAB | 02 | N | BORTEZOMIB + MELPHALAN | 100727658 |
| 10443658 | 10041912 | 1.74 | 63.8 | 03 | 2015-12-14 | 2015-12-19 | null | 01 | N | FLAIR TRIAL | 100368663 |
| 10443699 | 10041913 | 1.68 | 59.8 | null | 2019-02-26 | 2019-02-26 | CAPECITABINE + TEMOZOLOMIDE | 2 | N | BORTEZOMIB + MELPHALAN | 100521879 |
| 10443710 | 10041914 | null | 0 | Palliative (P) | null | 2020-10-27 | LENVATINIB | null | null | FLAIR TRIAL | 101082057 |
| 10443746 | 10041915 | 1.69 | 72 | Palliative (P) | 2018-12-22 | 2018-12-22 | AML 19 TRIAL | 02 | N | LETROZOLE + PALBOCICLIB | 101268591 |
| 10443771 | 10041916 | 1.63 | 63.6 | Palliative (P) | 2019-12-12 | 2019-12-13 | Carboplatin+Fluorouracil 4 or 5 day | 02 | N | DOXORUBICIN EMBOLISATION | 101318243 |
| 10443867 | 10041917 | 0 | 96.1 | Palliative (P) | 2017-01-11 | 2017-01-28 | Cisplatin + Pemetrexed | N | N | DOXORUBICIN EMBOLISATION | 101144091 |
| 10443874 | 10041918 | null | null | null | 2020-01-30 | 2020-02-13 | Arsenic Triox + Tretinoin Ind W1-4 | 02 | null | OFATUMUMAB | 101253157 |
| 10443885 | 10041919 | null | 103.7 | null | 2017-08-12 | 2017-08-24 | null | 02 | null | DACOMITINIB | 101100238 |
| 10444023 | 10041921 | 1.81 | 61 | Disease modification (D) | 2017-12-06 | 2017-12-09 | Cyclophosphamide + Docetaxel + Trastuzumab | N | N | CISPLATIN + EPIRUBICIN + FLUOROURACIL | 101830502 |
| 10444106 | 10041923 | 0 | 55.9 | Palliative (P) | 2016-10-11 | 2016-10-20 | AXITINIB | 02 | N | CISPLATIN + ETOPOSIDE | 101678517 |
| 10444165 | 10041924 | 0 | 70.25 | 03 | 2019-04-29 | 2019-05-02 | IDELALISIB + RITUXIMAB | 02 | null | NILOTINIB | 100926689 |
| 10444223 | 10041925 | 1.72 | 66.8 | Palliative (P) | 2019-06-01 | 2019-06-20 | GDP | 02 | N | CAPECITABINE + STREPTOZOCIN | 100703262 |
| 10444313 | 10041927 | 1.61 | 47 | Neo-adjuvant (N) | 2020-06-02 | 2020-06-16 | MPV (cycle 1-4) | 02 | N | CARBOPLATIN + LIPOSOMAL DOX | 100226994 |
| 10444458 | 10041928 | 1.73 | 77.2 | Palliative (P) | null | 2018-05-03 | FEC + DOCETAXEL | 99 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + RITUXIMAB + VINCRISTINE | 100069269 |
| 10444464 | 10041929 | 1.68 | 83.4 | Palliative (P) | 2016-10-01 | 2016-10-07 | TIP | 01 | N | BLEOMYCIN + DACARBAZINE + DOXORUBICIN + VINBLASTINE | 101142185 |
| 10444499 | 10041930 | 1.78 | 90 | Curative (C) | 2018-03-22 | 2018-03-27 | Vemurafenib | 02 | null | ATEZOLIZUMAB | 100413938 |
| 10444611 | 10041932 | 1.73 | 80.9 | null | 2022-03-29 | 2022-04-03 | ATEZOLIZUMAB + BEVACIZUMAB | 02 | null | ATEZOLIZUMAB + BEVACIZUMAB | 101253243 |
| 10444733 | 10041934 | 1.78 | 60 | null | 2019-11-30 | 2019-11-30 | null | N | N | VEMURAFENIB | 100441369 |
| 10444770 | 10041935 | 1.66 | 70.5 | 03 | 2020-08-12 | 2020-08-17 | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 02 | N | GEMCITABINE + OXALIPLATIN + RITUXIMAB | 101371771 |
| 10444774 | 10041936 | 0 | null | Palliative (P) | 2017-06-28 | 2017-07-10 | CTD Attenuated (Thalidomide 100mg) | 02 | N | DASATINIB | 101065119 |
| 10444945 | 10041939 | 1.8 | 89.4 | Curative (C) | 2017-02-21 | 2017-02-27 | null | 02 | N | CISPLATIN + EPIRUBICIN + FLUOROURACIL | 101669086 |
| 10444972 | 10041940 | 1.5 | 70.7 | Palliative (P) | 2019-01-02 | 2019-01-21 | Atezolizumab | 02 | Y | ATEZOLIZUMAB + NAB-PACLITAXEL | 100146882 |
| 10445051 | 10041941 | null | null | Curative (C) | null | 2016-05-01 | Letrozole + Palbociclib | null | N | BUSULPHAN | 100215397 |
| 10445052 | 10041942 | 1.85 | null | Palliative (P) | 2016-02-16 | 2016-02-28 | ECX | 02 | N | CABAZITAXEL | 100674598 |
| 10445399 | 10041946 | 1.61 | 65.6 | 03 | 2018-07-29 | 2018-12-12 | Cisplatin + Pemetrexed | 02 | N | AML18 TRIAL | 100709390 |
| 10445711 | 10041949 | null | null | Not known (9) | 2018-09-01 | 2018-09-01 | Cisplatin + Etoposide po | 02 | N | CISPLATIN + RT | 100429171 |
| 10445901 | 10041952 | 1.75 | 41.1 | Adjuvant (A) | 2019-09-27 | 2019-10-03 | LANREOTIDE | 02 | N | CETUXIMAB | 101725159 |
| 10445930 | 10041953 | 0 | 64 | null | 2020-08-03 | 2020-08-07 | null | 02 | null | CISPLATIN + RT | 100953445 |
| 10446238 | 10041956 | 1.56 | 102 | Neo-adjuvant (N) | null | 2019-11-26 | MASITINIB | N | N | EVEROLIMUS | 100610272 |
| 10446335 | 10041959 | 1.61 | 41.1 | Palliative (P) | 2019-01-15 | 2019-02-07 | Everolimus 10mg | 02 | Y | PACLITAXEL + TRASTUZUMAB | 101013370 |
| 10446372 | 10041960 | 1.69 | 57 | Disease modification (D) | null | 2015-08-03 | CAP | N | N | LIPOSOMAL DAUNORUBICIN + LIPOSOMAL CYTARABINE (VYXEOS) | 100176734 |
| 10446379 | 10041961 | 1.62 | 75.6 | null | 2021-07-24 | 2021-08-08 | Ipilimumab | 02 | null | BLEOMYCIN | 100803816 |